Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease

Author:

Muir Andrew J.1,Levy Cynthia2,Janssen Harry L.A.3,Montano‐Loza Aldo J.4,Shiffman Mitchell L.5,Caldwell Stephen6,Luketic Velimir7,Ding Dora8,Jia Catherine8,McColgan Bryan J.8,McHutchison John G.8,Mani Subramanian G.8,Myers Robert P.8,Manns Michael9,Chapman Roger10,Afdhal Nezam H.11,Goodman Zachary12,Eksteen Bertus13,Bowlus Christopher L.14,

Affiliation:

1. Duke Clinical Research Institute Durham NC

2. University of Miami Miami FL

3. Toronto Centre for Liver Disease Toronto ON Canada

4. University of Alberta Edmonton AB Canada

5. Liver Institute of Virginia Richmond VA

6. University of Virginia Charlottesville VA

7. Virginia Commonwealth University Richmond VA

8. Gilead Sciences, Inc Foster City CA

9. Hannover Medical School Hannover Germany

10. University of Oxford Oxford UK

11. Beth Israel Deaconess Medical Center and Harvard Medical School Boston MA

12. Inova Fairfax Hospital Falls Church VA

13. Aspen Woods Clinic Calgary AB Canada

14. University of California at Davis Sacramento CA

Funder

Gilead Sciences

Publisher

Wiley

Subject

Hepatology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3